Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 2Ganglioneuroblastoma 2Sarcoma, Myeloid 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleuropulmonary blastoma 1PRETEXT I Hepatoblastoma 1Neuroblastoma 1Myeloproliferative Disorders 1Localized Extraskeletal Ewing Sarcoma 1Leukemia, Biphenotypic, Acute 1Burkitt Lymphoma 1Blast Crisis 1

Interventions

Cytarabine 4venetoclax 2Mitoxantrone 2Daunorubicin 2Cladribine 2thymoglobulin 1quizartinib 1pegylated granulocyte colony-stimulating factor 1fludarabine phosphate 1fludarabine 1blinatumomab 1Transplantation 1Thiotepa 1Tacrolimus 1Sorafenib 1Sirolimus 1Rituximab 1Razoxane 1Mesna 1Melphalan 1Leyk 1Idarubicin 1Granulocyte Colony-Stimulating Factor 1Gemtuzumab 1Filgrastim 1Etoposide 1Dexrazoxane 1Cyclophosphamide 1Bortezomib 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Myeloid × Razoxane × 1 year × Clear all
NCT03589729 2026-05-22

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

M.D. Anderson Cancer Center

Phase 2 Recruiting
100 enrolled
MyeloidOther hematologic neoplasmSarcoma

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡